Document Detail


SC-2001 Overcomes STAT3-mediated Sorafenib Resistance through RFX-1/SHP-1 Activation in Hepatocellular Carcinoma.
MedLine Citation:
PMID:  25047655     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Hepatocellular carcinoma is the fifth most common solid cancer worldwide. Sorafenib, a small multikinase inhibitor, is the only approved therapy for advanced HCC. The clinical benefit of sorafenib is offset by the acquisition of sorafenib resistance. Understanding of the molecular mechanism of STAT3 overexpression in sorafenib resistance is critical if the clinical benefits of this drug are to be improved. In this study, we explored our hypothesis that loss of RFX-1/SHP-1 and further increase of p-STAT3 as a result of sorafenib treatment induces sorafenib resistance as a cytoprotective response effect, thereby, limiting sorafenib sensitivity and efficiency. We found that knockdown of RFX-1 protected HCC cells against sorafenib-induced cell apoptosis and SHP-1 activity was required for the process. SC-2001, a molecule with similar structure to obatoclax, synergistically suppressed tumor growth when used in combination with sorafenib in vitro and overcame sorafenib resistance through up-regulating RFX-1 and SHP-1 resulting in tumor suppression and mediation of dephosphorylation of STAT3. In addition, sustained sorafenib treatment in HCC led to increased p-STAT3 which was a key mediator of sorafenib sensitivity. The combination of SC-2001 and sorafenib strongly inhibited tumor growth in both wild-type and sorafenib-resistant HCC cell bearing xenograft models. These results demonstrate that inactivation of RFX/SHP-1 induced by sustained sorafenib treatment confers sorafenib resistance to HCC through p-STAT3 up-regulation. These effects can be overcome by SC-2001 through RFX-1/SHP-1 dependent p-STAT3 suppression. In conclusion, the use of SC-2001 in combination with sorafenib may constitute a new strategy for HCC therapy.
Authors:
Jung-Chen Su; Ping-Hui Tseng; Szu-Hsien Wu; Cheng-Yi Hsu; Wei-Tien Tai; Yong-Shi Li; I-Ting Chen; Chun-Yu Liu; Kuen-Feng Chen; Chung-Wai Shiau
Related Documents :
24469795 - Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosoma...
24968265 - The rest gene signature predicts drug sensitivity in neuroblastoma cell lines and is si...
23550645 - Mir-17-92: a polycistronic oncomir with pleiotropic functions.
24243565 - Preclinical trial of a new dual mtor inhibitor, mln0128, using renal cell carcinoma tum...
15334065 - Tumor formation in p53 mutant ovaries transplanted into wild-type female hosts.
15143345 - Analysis of the horseradish peroxidase/indole-3-acetic acid combination in a three-dime...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-7-18
Journal Detail:
Title:  Neoplasia (New York, N.Y.)     Volume:  -     ISSN:  1476-5586     ISO Abbreviation:  Neoplasia     Publication Date:  2014 Jul 
Date Detail:
Created Date:  2014-7-22     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100886622     Medline TA:  Neoplasia     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2014. Published by Elsevier Inc.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Neck transfixion for sacral extradural spinal meningeal cysts without spinal nerve root fibers.
Next Document:  Terrestrial Contributions to the Aquatic Food Web in the Middle Yangtze River.